Overexpression of a secretory leukocyte protease inhibitor in human gastric cancer

International Journal of Cancer

Volumn 123, Issue 8, 2008, Pages 1787-1796

  Cheng, Wan Li ^a   Wang, Chia Siu ^b   Huang, Ya Hui ^a   Liang, Ying ^a   Lin, Paul Y ^b   Hsueh, Chuen ^a   Wu, Yi Chin ^a   Chen, Wei Jan ^b   Yu, Chia Jung ^a   Lin, Sheue Rong ^c   Lin, Kwang Huei ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c Public Health Bureau Taoyuan County Government   (Taiwan)

Author keywords

Gastrointestinal neoplasms; Reverse transcriptase polymerase chain reaction; SLPI protein, human; Tumor markers

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; PARAFFIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CELL INVASION; CELL LINE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GASTRECTOMY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NORTHERN BLOTTING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; SEROSA; STOMACH CANCER; STOMACH MUCOSA; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; CELL GROWTH PROCESSES; CELL MOVEMENT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; STOMACH NEOPLASMS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 51949105336     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23746     Document Type: Article

References (47)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005;241:27-39.
3. Wang CS, Hsieh CC, Chao TC, Jan YY, Jeng LB, Hwang TL, Chen MF, Chen PC, Chen JS, Hsueh S. Resectable gastric cancer: operative mortality and survival analysis. Chang Gung Med J 2002;25:216-27.
4. Marrelli D, Roviello F, De Stefano A, Fametani M, Garosi L, Messano A, Pinto E. Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. Oncology 1999;57:55-62.
5. Lauren P. Histogenesis of intestinal and diffuse types of gastric carcinoma. Scand J Gastroenterol Suppl 1991;180:160-4.
6. Tahara E. Molecular mechanism of stomach carcinogenesis. J Cancer Res Clin Oncol 1993;119:265-72.
7. Cervantes A, Rodriguez Braun E, Perez Fidalgo A, Chirivella Gonzalez I. Molecular biology of gastric cancer. Clin Transl Oncol 2007;9:208-15.
8. Yasui W, Oue N, Kuniyasu H, Ito R, Tahara E, Yokozaki H. Molecular diagnosis of gastric cancer: present and future. Gastric Cancer 2001;4:113-21.
9. Kim KM, Kwon MS, Hong SJ, Min KO, Seo EJ, Lee KY, Choi SW, Rhyu MG. Genetic classification of intestinal-type and diffuse-type gastric cancers based on chromosomal loss and microsatellite instability. Virchows Arch 2003;443:491-500.
10. Allgayer H, Heiss MM, Schildberg FW. Prognostic factors in gastric cancer. Br J Surg 1997;84:1651-64.
11. Pusztai L, Ayers M, Stec J, Hortobagyi GN. Clinical application of cDNA microarrays in oncology. Oncologist 2003;8:252-8.
12. Ransohoff DF. Cancer: developing molecular biomarkers for cancer. Science 2003;299:1679-80.
13. Wang CS, Lin KH, Chen SL, Chan YF, Hsueh S. Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance. Br J Cancer 2004;91:1924-30.
14. Devoogdt N, Hassanzadeh Ghassabeh G, Zhang J, Brys L, De Baetselier P, Revets H. Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc Natl Acad Sci USA 2003;100:5778-82.
15. Devoogdt N, Revets H, Ghassabeh GH, De Baetselier P. Secretory leukocyte protease inhibitor in cancer development. Ann NY Acad Sci 2004;1028:380-9.
16. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 2nd English edn. Gastric Cancer 1998;1:10-24.
17. Sobin LH, Fleming ID. TNM classification of malignant tumors, 5th edn (1997). Cancer 1997;80:1803-4.
18. Huang YH, Lee CY, Tai PJ, Yen CC, Liao CY, Chen WJ, Liao CJ, Cheng WL, Chen RN, Wu SM, Wang CS, Lin KH. Indirect regulation of human dehydroepiandrosterone sulfotransferase family 1A member 2 by thyroid hormones. Endocrinology 2006;147:2481-9.
19. Tai PJ, Huang YH, Shih CH, Chen RN, Chen CD, Chen WJ, Wang CS, Lin KH. Direct regulation of androgen receptor-associated protein 70 by thyroid hormone and its receptors. Endocrinology 2007;148:3485-95.
20. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
21. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
22. Ameshima S, Ishizaki T, Demura Y, Imamura Y, Miyamori I, Mitsuhashi H. Increased secretory leukoprotease inhibitor in patients with nonsmall cell lung carcinoma. Cancer 2000;89:1448-56.
23. Lin KH, Wang WJ, Wu YH, Cheng SY. Activation of antimetastatic Nm23-H1 gene expression by estrogen and its alpha-receptor. Endocrinology 2002;143:467-75.
24. Taggart CC, Lowe GJ, Greene CM, Mulgrew AT, O'Neill SJ, Levine RL, McElvaney NG. Cathepsin B, L and S cleave and inactivate secretory leucoprotease inhibitor. J Biol Chem 2001;276:33345-52.
25. Sugino T, Yamaguchi T, Ogura G, Kusakabe T, Goodison S, Homma Y, Suzuki T. The secretory leukocyte protease inhibitor (SLPI) suppresses cancer cell invasion but promotes blood-borne metastasis via an invasion-independent pathway. J Pathol 2007;212:152-60.
26. Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ. Coordinately up-regulated genes in ovarian cancer. Cancer Res 2001;61:3869-76.
27. Alkemade HA, van Vlijmen-Willems IM, van Haelst UJ, van de Kerkhof PC, Schalkwijk J. Demonstration of skin-derived antileukoproteinase (SKALP) and its target enzyme human leukocyte elastase in squamous cell carcinoma. J Pathol 1994;174:121-9.
28. Kluger HM, Kluger Y, Gilmore-Hebert M, DiVito K, Chang JT, Rodov S, Mironenko O, Kacinski BM, Perkins AS, Sapi E. cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model. Lab Invest 2004;84:320-31.
29. Hu Y, Sun H, Drake J, Kittrell F, Abba MC, Deng L, Gaddis S, Sahin A, Baggerly K, Medina D, Aldaz CM. From mice to humans: identification of commonly deregulated genes in mammary cancer via comparative SAGE studies. Cancer Res 2004;64:7748-55.
30. Hippo Y, Taniguchi H, Tsutsumi S, Machida N, Chong JM, Fukayama M, Kodama T, Aburatani H. Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res 2002;62:233-40.
31. Inoue H, Matsuyama A, Mimori K, Ueo H, Mori M. Prognostic score of gastric cancer determined by cDNA microarray. Clin Cancer Res 2002;8:3475-9.
32. Leung SY, Chen X, Chu KM, Yuen ST, Mathy J, Ji J, Chan AS, Li R, Law S, Troyanskaya OG, Tu IP, Wong J, et al. Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. Proc Natl Acad Sci USA 2002;99:16203-8.
33. Hasegawa S, Furukawa Y, Li M, Satoh S, Kato T, Watanabe T, Katagiri T, Tsunoda T, Yamaoka Y, Nakamura Y. Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23,040 genes. Cancer Res 2002;62:7012-17.
34. Terashima M, Maesawa C, Oyama K, Ohtani S, Akiyama Y, Ogasawara S, Takagane A, Saito K, Masuda T, Kanzaki N, Matsuyama S, Hoshino Y, et al. Gene expression profiles in human gastric cancer: expression of maspin correlates with lymph node metastasis. Br J Cancer 2005;92:1130-6.
35. Meireles SI, Cristo EB, Carvalho AF, Hirata R, Jr, Pelosof A, Gomes LI, Martins WK, Begnami MD, Zitron C, Montagnini AL, Soares FA, Neves EJ, et al. Molecular classifiers for gastric cancer and nonmalignant diseases of the gastric mucosa. Cancer Res 2004;64:1255-65.
36. Vecchi M, Nuciforo P, Romagnoli S, Confalonieri S, Pellegrini C, Serio G, Quarto M, Capra M, Roviaro GC, Contessini Avesani E, Corsi C, Coggi G, et al. Gene expression analysis of early and advanced gastric cancers. Oncogene 2007;26:4284-94.
37. Fukui R, Nishimori H, Hata F, Yasoshima T, Ohno K, Yanai Y, Kamiguchi K, Denno R, Sato N, Hirata K. Inhibitory effect of endothelin A receptor blockade on tumor growth and liver metastasis of a human gastric cancer cell line. Gastric Cancer 2007;10:123-8.
38. Haraguchi N, Inoue H, Mimori K, Tanaka F, Utsunomiya T, Yoshikawa K, Mori M. Analysis of gastric cancer with cDNA microarray. Cancer Chemother Pharmacol 2004;54(Suppl 1):S21-S24.
39. Zhang D, Simmen RC, Michel FJ, Zhao G, Vale-Cruz D, Simmen FA. Secretory leukocyte protease inhibitor mediates proliferation of human endometrial epithelial cells by positive and negative regulation of growth-associated genes. J Biol Chem 2002;277:29999-30009.
40. Ashcroft GS, Lei K, Jin W, Longenecker G, Kulkami AB, Greenwell-Wild T, Hale-Donze H, McGrady G, Song XY, Wahl SM. Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. Nat Med 2000;6:1147-53.
41. Tian X, Shigemasa K, Hirata E, Gu L, Uebaba Y, Nagai N, O'Brien TJ, Ohama K. Expression of human kallikrein 7 (hK7/SCCE) and its inhibitor antileukoprotease (ALP/SLPI) in uterine endocervical glands and in cervical adenocarcinomas. Oncol Rep 2004;12:1001-6.
42. Wex T, Treiber G, Venerito M, Leodolter A, Peitz U, Kuester D, Hritz I, Krueger S, Roessner A, Malfertheiner P. Helicobacter pylori- induced downregulation of the secretory leukocyte protease inhibitor (SLPI) in gastric epithelial cell lines and its functional relevance for H. pylori-mediated diseases. Biol Chem 2006;387:893-901.
43. Wu CM, Lee YS, Wang TH, Lee LY, Kong WH, Chen ES, Wei ML, Liang Y, Hwang TL. Identification of differential gene expression between intestinal and diffuse gastric cancer using cDNA microarray. Oncol Rep 2006;15:57-64.
44. Trojan L, Schaaf A, Steidler A, Haak M, Thalmann G, Knoll T, Gretz N, Alken P, Michel MS. Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines. Anticancer Res 2005;25:183-91.
45. Wang N, Thuraisingam T, Fallavollita L, Ding A, Radzioch D, Brodt P. The secretory leukocyte protease inhibitor is a type 1 insulin-like growth factor receptor-regulated protein that protects against liver metastasis by attenuating the host proinflammatory response. Cancer Res 2006;66:3062-70.
46. Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K. Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis. Gynecol Oncol 2005;96:516-19.
47. Zhang Y, DeWitt DL, McNeely TB, Wahl SM, Wahl LM. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. J Clin Invest 1997;99:894-900.